| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 181 | METHODS OF DIAGNOSING CLOSTRIDIUM DIFFICILE INFECTION OR RECURRENCE IN A SUBJECT | US15841453 | 2017-12-14 | US20180164282A1 | 2018-06-14 | Mary Elizabeth Yacyshyn; Bruce R. Yacyshyn; Julianne Qualtieri |
| Methods are described for identifying CDI patients as well as CDI patients at risk for recurrence. Embodiments include: (1) flow cytometry of circulating peripheral blood mononuclear cells (PBMC) to phenotype for the less efficient immunoglobulin response to bacterial toxins and surface antigens that characterizes patients who will become recurrent; (2) stratification by means of complete blood count (CBC) using a Coulter counter to detect the differences in lower angle light scatter (LAL), which has a larger range in the recurrent population; and (3) stratification by means of complete blood count (CBC) using a Coulter counter to detect the lower axial light loss (AL2) exhibited in recurrent patients. | ||||||
| 182 | Methods and compositions for determining and treating relapse in inflammatory bowel disease | US14890257 | 2014-05-13 | US09995752B2 | 2018-06-12 | Lee A. Denson; Bruce C. Trapnell; Jan Däbritz |
| Described are methods and compositions for evaluating the relapse risk n subjects having an inflammatory bowel disease (IBD). Some embodiments include selecting a treatment for an evaluated IBD relapse risk in a subject. | ||||||
| 183 | SYSTEM AND METHOD FOR DETERMINING RISK OF DIABETES BASED ON BIOCHEMICAL MARKER ANALYSIS | US15886698 | 2018-02-01 | US20180156815A1 | 2018-06-07 | Pertti Hurskainen; Teemu Korpimäki; Heikki Kouru; Mikko Sairanen |
| A method for predicting risk of gestational diabetes mellitus (GDM) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of PAI-2 and sTNFR1, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing GDM. | ||||||
| 184 | PROGNOSIS OF ADVERSE EVENTS IN PATIENTS WITH SUSPECTED CHRONIC HEART FAILURE | US15693880 | 2017-09-01 | US20170370940A1 | 2017-12-28 | Joachim STRUCK; John GF CLELAND |
| The present invention is in the field of clinical diagnostics. Particularly the present invention relates to the prognosis of adverse events in patients with stable chronic heart failure or being suspected of having stable chronic heart failure by determination of the level of Procalcitonin (PCT). | ||||||
| 185 | SIGNATURES AND PCDETERMINANTS ASSOCIATED WITH PROSTATE CANCER AND METHODS OF USE THEREOF | US15337966 | 2016-10-28 | US20170299594A1 | 2017-10-19 | Ronald A. Depinho; Zhihu Ding; Lynda Chin |
| The present invention provides methods of detecting cancer using biomarkers. | ||||||
| 186 | BIOMARKERS AND USES THEREOF IN PROGNOSIS AND TREATMENT STRATEGIES FOR RIGHT-SIDE COLON CANCER DISEASE AND LEFT-SIDE COLON CANCER DISEASE | US15276131 | 2016-09-26 | US20170283877A1 | 2017-10-05 | Steven Buechler; Amanda B. Hummon |
| Genetic biomarkers for left side colon cancer (LCC) (such as expression levels of an RNA transcript or expression product of NOX4, MMP3, or a combination) and right side colon cancer (RCC) (such as expression levels of an RNA transcript or expression product of CDCX2, FAM69A, or a combination), are disclosed. Methods for using the biomarkers in providing a prognosis of relapse-free survival probability in patients having LCC or RCC are also presented. Prognostic panels using gene expression values of the biomarkers are also presented. Computer implemented methods employing the biomarkers, and as well as for determining relapse-free survival probability in a patient having RCC or LCC are provided. A genetic method for classifying a colon cancer tissue as a RCC or as a LCC is also disclosed. | ||||||
| 187 | COMPOSITIONS FOR TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA AND METHODS OF USE THEREOF | US15500456 | 2015-07-30 | US20170252364A1 | 2017-09-07 | Smadar AVIGAD; Isaac YANIV; Keren SHICHRUR |
| Provided herein are compositions for treatment of Acute Lymphoblastic Leukemia (ALL) and methods of their use, including inhibiting ALL relapse. Further provided herein are systems of treatment that are directed by a health care provider, and which combine prognostic methods for determining ALL relapse and the described treatments. | ||||||
| 188 | PREDICTION OF THE SUSCEPTIBILITY OF AN AT RISK PATIENT FOR DEVELOPING OR REDEVELOPING CLOSTRIDIUM DIFFICILE INFECTION | US15519724 | 2015-10-16 | US20170242006A1 | 2017-08-24 | Agnès FOUSSADIER; Mark MILLER |
| A method for prediction of the susceptibility of an at risk patient to developing or redeveloping an infection with Clostridium difficile, having the determination by immunoassay, in a stool sample from said patient, of the level of antibody IgA anti-toxin B of Clostridium difficile, and comparing this level with a reference value S determined beforehand using two populations of patients exposed to the bacterium, one population not having developed or redeveloped such an infection and the other population having developed or redeveloped such an infection, —a level lower than said reference value S signifying that the patient is a patient with a heightened risk of developing or redeveloping a Clostridium difficile infection, and —a level higher than said reference value S signifying that the patient is not a patient with a heightened risk of developing or redeveloping a Clostridium difficile infection. | ||||||
| 189 | MIR-193A-3P AND ASSOCIATED GENES PREDICT TUMORIGENESIS AND CHEMOTHERAPY OUTCOMES | US15367947 | 2016-12-02 | US20170218457A1 | 2017-08-03 | Jingde Zhu |
| The disclosure provides a correlation between the expression level of the miR-193a gene, which can be regulated by its methylation status, and both tumorigenesis of and the resistance of a cancer cell to a pyrimidine antimetabolite (5-FU) based chemotherapy. In addition to the methylation status and the expression of miR-193a, its downstream genes, such as E2F1, SRSF2, and apoptotic genes such as caspase 2, are also involved and can serve as useful markers for cancer therapy prognosis and for therapy selection. | ||||||
| 190 | Prediction of recurrence for bladder cancer by a protein signature in tissue samples | US14124580 | 2012-06-08 | US09678075B2 | 2017-06-13 | Christoph Schröder; Harish Srinivasan; Jörg Hoheisel; François Radvanyi |
| The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown in Table, and comparing the amount of said at least one biomarker with a reference amount for said at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted. The present invention also contemplates a method for identifying a subject being in need of a further bladder cancer therapy. Encompassed are, furthermore, diagnostic devices and kits for carrying out said methods. | ||||||
| 191 | CANCER PROGNOSIS SIGNATURES | US15331076 | 2016-10-21 | US20170137890A1 | 2017-05-18 | Jerry Lanchbury; Alexander Gutin; Darl Flake |
| The disclosure provides for molecular classification of disease and, particularly, molecular markers for breast cancer prognosis and methods and systems of use thereof. | ||||||
| 192 | DIAGNOSTIC AND PROGNOSTIC MARKERS FOR CANCER | US15272396 | 2016-09-21 | US20170082629A1 | 2017-03-23 | Frank M. Torti; Suzy V. Torti; Lance Miller |
| Compositions and methods useful for diagnosis and prognosis of cancer are provided. | ||||||
| 193 | DIAGNOSTIC ANTI-CD95L ANTIBODY | US15335297 | 2016-10-26 | US20170044264A1 | 2017-02-16 | Harald Fricke; Christian GIEFFERS; Jaromir Sykora |
| The present invention relates to a specific CD95L antibody and to the use thereof in the diagnosis of a cancer disease. | ||||||
| 194 | METHODS AND BIOMARKERS FOR ANALYSIS OF COLORECTAL CANCER | US15302728 | 2015-04-10 | US20170038386A1 | 2017-02-09 | Ragnhild A. Lothe; Jarle Bruun; Matthias Kolberg; Rolf Inge Skotheim; Guro Elisabeth Lind; Arild Nesbakken |
| The present invention relates to methods and biomarkers (e.g., protein biomarkers) for detection of colorectal cancer in biological samples (e.g., tissue samples, biopsy samples, stool samples, blood samples, plasma samples, serum samples). In some embodiments, methods and biomarkers of the present invention find use in detection of colon cancer, providing a prognosis to colorectal cancer patients, and in companion diagnostics. | ||||||
| 195 | MIR-193A-3P and associated genes predict tumorigenesis and chemotherapy outcomes | US14807647 | 2015-07-23 | US09540698B2 | 2017-01-10 | Jingde Zhu |
| The disclosure provides a correlation between the expression level of the miR-193a gene, which can be regulated by its methylation status, and both tumorigenesis of and the resistance of a cancer cell to a pyrimidine antimetabolite (5-FU) based chemotherapy. In addition to the methylation status and the expression of miR-193a, its downstream genes, such as E2F1, SRSF2, and apoptotic genes such as caspase 2, are also involved and can serve as useful markers for cancer therapy prognosis and for therapy selection. | ||||||
| 196 | BCR-ABL truncation mutations | US12892679 | 2010-09-28 | US09488656B2 | 2016-11-08 | Maher Albitar; Wanlong Ma |
| Truncation variants of BCR-ABL mRNA that produces BCR-ABL proteins with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is described. Vectors for expressing the truncated gene products are described as well as recombinant cells that express the truncated gene products from cDNA constructs. Also provided are methods compositions and kits for detecting the BCR-ABL truncation variants. Also provided are methods for determining the prognosis of a patient diagnosed as having myeloproliferative disease, and methods for predicting the likelihood for resistance to a treatment with tyrosine kinase inhibitor in a patient diagnosed as having myeloproliferative disease. Additionally, methods for screening BCR-ABL tyrosine kinase domain inhibitors which rely on the recombinant cells are also disclosed. | ||||||
| 197 | Anti-FGFR2 antibodies and pharmaceutical compositions thereof | US14791698 | 2015-07-06 | US09481733B2 | 2016-11-01 | Toshiaki Ohtsuka; Chigusa Yoshimura; Toshinori Agatsuma; Atsushi Urano; Takako Kimura; Yumi Matsui; Tatsuji Matsuoka; Jun Hasegawa; Yasuki Kamai; Reimi Kawaida |
| The present invention provides an antibody which binds to a fibroblast growth factor receptor. | ||||||
| 198 | MONOCLONAL ANTI-TK1 ANTIBODIES | US15105999 | 2014-12-18 | US20160311927A1 | 2016-10-27 | Staffan Eriksson |
| The embodiments relate to monoclonal antibodies or fragments capable of binding to a serum form of human TK1 and to kits and methods involving the use of such monoclonal antibodies or fragments. | ||||||
| 199 | Methods Predicting Risk of an Adverse Clinical Outcome | US14993196 | 2016-01-12 | US20160299153A1 | 2016-10-13 | James V. Snider |
| Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 in a biological sample from the subject and determining a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to ST2, an antibody that specifically binds to galectin-3, and instructions for using the kit to evaluate the risk of an adverse clinical outcome in a subject, to decide whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis) or to initiate or terminate treatment, to select a subject for participation in a clinical study, and/or to select treatment for a subject. | ||||||
| 200 | Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease | US14454552 | 2014-08-07 | US09464328B2 | 2016-10-11 | Steven Buechler; Amanda B. Hummon |
| Genetic biomarkers for left side colon cancer (LCC) (such as expression levels of an RNA transcript or expression product of NOX4, MMP3, or a combination) and right side colon cancer (RCC) (such as expression levels of an RNA transcript or expression product of CDCX2, FAM69A, or a combination), are disclosed. Methods for using the biomarkers in providing a prognosis of relapse-free survival probability in patients having LCC or RCC are also presented. Prognostic panels using gene expression values of the biomarkers are also presented. Computer implemented methods employing the biomarkers, and as well as for determining relapse-free survival probability in a patient having RCC or LCC are provided. A genetic method for classifying a colon cancer tissue as a RCC or as a LCC is also disclosed. | ||||||
QQ群二维码
意见反馈
意见反馈